Maxim Group LLC Expands Equity Research Division With the Appointment of a Senior Biotechnology Analyst
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 05/02/12 -- Maxim Group LLC, a leading full service investment banking, securities and wealth management firm, announced the appointment of Jason Kolbert as a Senior Biotechnology Analyst.
"I am pleased to add someone with Jason's deep industry knowledge and diverse experience to our healthcare platform. Healthcare is a core vertical at Maxim Group and biotechnology is an important component," said Anthony Vendetti, Director of Research at Maxim Group LLC.
Mr. Kolbert has worked extensively in the Healthcare sector as product manager for a leading pharmaceutical company, a fund manager and as an equity analyst. Prior to joining Maxim Group, he spent seven years at Susquehanna International Group where he managed a healthcare fund and later founded SIG's sell-side biotechnology team. Previously, Mr. Kolbert served as the healthcare strategist for Salomon Smith Barney. He is frequently quoted in Barron's and is regularly featured on CNBC. Prior to beginning his Wall Street career, Mr. Kolbert served as a product manager for Schering-Plough in Osaka, Japan. He received a B.S. in Chemistry from SUNY New Paltz, and an MBA from the University of New Haven.
Maxim Group LLC is a full-service investment banking firm headquartered in New York. Maxim Group provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales and trading as well as equity research. The investment banking group focuses on middle market and emerging growth companies within the shipping, energy, health care, technology, retail, and business and financial services sectors. The institutional coverage of Maxim Group spans North and South America, Europe and Asia. Maxim Group LLC is a registered as a broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc. To learn more about Maxim Group, visit .
For further information please contact:
John J. Garrity
Chief Marketing Officer
212.895.3624
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 02.05.2012 - 12:00 Uhr
Sprache: Deutsch
News-ID 141618
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Commercial & Investment Banking
Diese Pressemitteilung wurde bisher 165 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Maxim Group LLC Expands Equity Research Division With the Appointment of a Senior Biotechnology Analyst"
steht unter der journalistisch-redaktionellen Verantwortung von
Maxim Group (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
